Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Co-CaReD

Financiado

In-cell Redox Catalysis by Co(III) Metallodrugs as New Tools for Cancer Treatmen...

In-cell Redox Catalysis by Co(III) Metallodrugs as New Tools for Cancer Treatments The search of new therapies for cancer is a primary EU mission. In-cell redox catalysis promoted by organometallic complexes of precious metals as Ru(II), Os(II), Rh(III) and Ir(III) is a novel promising concept to access more eff... ver más

27/08/2026

FUNDACION IMDEA NA...

165K€

Presupuesto del proyecto: 165K€

Líder del proyecto

FUNDACION IMDEA NANOCIENCIA Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion

TRL 4-5 | 130K€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-28

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

FUNDACION IMDEA NANOCIENCIA

165.31K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CTQ2014-60100-R ACTIVATABLE METALLODRUGS FOR NEW NANOINSPIRED ANTICANCER TOO... 80K€ Cerrado

MET-EFFECT Metal complexes of a naturally inspired framework functional... 764K€ Cerrado

PID2020-117766GB-I00 DISEÑO DE POTENTES METALOFARMACOS Y SU SEGUIMIENTO EN EL NAN... 158K€ Cerrado

RTI2018-096891-B-I00 DISEÑO Y DESARROLLO DE NUEVOS COMPLEJOS DE METALES NOBLES LU... 149K€ Cerrado

RTI2018-100709-B-C22 NUEVOS METALOFARMACOS DISEÑADOS PARA INCREMENTAR LA SELECTIV... 57K€ Cerrado

PID2021-127187OB-C22 ESTRATEGIAS AVANZADAS EN EL DISEÑO DE FOTOSENSIBILIZADORES B... 91K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2023-06-28
Fecha Fin: 2026-08-27

Líder del proyecto

FUNDACION IMDEA NANOCIENCIA Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion

TRL 4-5 | 130K€

Presupuesto del proyecto 165K€

Descripción del proyecto The search of new therapies for cancer is a primary EU mission. In-cell redox catalysis promoted by organometallic complexes of precious metals as Ru(II), Os(II), Rh(III) and Ir(III) is a novel promising concept to access more efficient, safer, and less invasive medicines. Co-CaReD aims to design new in-cell catalytic systems based on half-sandwich Co(III) complexes. Cobalt combines effective catalytic performances for biomedical applications and high catalytic versatility. Moreover, it is a cheap, sustainable, and biocompatible metal whose peculiar chemical properties can access unique reactivity pathways. The project will focus on the development of new synthetic catalysts, on their applications in redox reactions of therapeutic interest, involving known examples and unprecedent cases of study, and on the unveiling of their biological mechanism of action in cancer cells. Co-CaReD will be implemented in a vibrant and stimulating research environment at IMDEA Nanociencia, in Dr. Ana Pizarro research group. The project will benefit of the complementary expertise of the ER in organometallic chemistry and redox catalysis and of the supervisor in studying the intracellular reactivity at the molecular level of metal-based drugs. An intense training plan is designed to equip the researcher with the necessary skills to study the biological activity of the Co(III) catalysts – including single-cell studies – and to design proof-of-concept experiments that confirm the occurrence of a metal-based catalytic reactivity inside the human cells. The main goal of Co-CaReD is to generate novel redox catalytic systems based on more biocompatible, less toxic, and cheaper cobalt drug candidates, as complementary tools to noble metal complexes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores